JIN-LONG CHEN - 13 Sep 2021 Form 4 Insider Report for NGM BIOPHARMACEUTICALS INC

Role
Chief Scientific Officer, Director
Signature
/s/ Jin-Long Chen
Issuer symbol
N/A
Transactions as of
13 Sep 2021
Net transactions value
-$775,306
Form type
4
Filing time
14 Sep 2021, 21:27:48 UTC
Previous filing
11 Aug 2021
Next filing
13 Oct 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NGM Common Stock Sale $100,313 -3,920 -0.41% $25.59* 955,529 13 Sep 2021 Direct F1, F2
transaction NGM Common Stock Sale $285,515 -10,910 -1.1% $26.17* 944,619 13 Sep 2021 Direct F1, F3
transaction NGM Common Stock Sale $4,587 -170 -0.02% $26.98* 944,449 13 Sep 2021 Direct F1, F4
transaction NGM Common Stock Sale $305,535 -11,963 -1.3% $25.54* 932,486 14 Sep 2021 Direct F1, F5
transaction NGM Common Stock Sale $79,357 -3,037 -0.33% $26.13* 929,449 14 Sep 2021 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 6, 2021.
F2 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $24.82 to $25.81. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $25.82 to $26.77. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $26.92 to $27.07. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $25.04 to $26.02. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
F6 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $26.05 to $26.19. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.